Analysis: Liraglutide's deadline not the only one FDA misses

09/9/2008 | TheRPMReport.com

The FDA is six months away from its scheduled ruling on Novo Nordisk's Type 2 diabetes drug liraglutide, but the agency said it will miss the deadline. According to this RPM Report analysis, the agency is missing more deadlines in general and may be extra cautious in this case, given the pancreatitis safety signal seen with Amylin Pharmaceuticals' exenatide.

View Full Article in:

TheRPMReport.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA